Analysis of complex biomarkers for human immune-mediated disorders based on cytokine responsiveness of peripheral blood cells

John Manley III Davis, Keith L Knutson, Michael A. Strausbauch, Cynthia Crowson, Terry M Therneau, Peter J. Wettstein, Eric Lawrence Matteson, Sherine E. Gabriel

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The advent of improved biomarkers promises to enhance the clinical care for patients with rheumatoid arthritis (RA) and other immune-mediated disorders. We have developed an innovative approach to broadly assess the cytokine responsiveness of human PBMCs using a multistimulant panel and multiplexed immunoassays. The objective of this study was to demonstrate this concept by determining whether cytokine profiles could discriminate RApatients according to disease stage (early versus late) or severity. A 10-cytokine profile, consisting of IL-12, CCL4, TNF-α, IL-4, and IL-10 release in response to stimulation with anti-CD3/anti-CD28, CXCL8 and IL-6 in response to CMVand EBV lysate, and IL-17A, GM-CSF, and CCL2 in response to human heat shock protein 60, easily discriminated the early RA group from controls. These data were used to create an immune response score, which performed well in distinguishing the early RA patients from controls and also correlated with several markers of disease severity among the patients with late RA. In contrast, the same 10-cytokine profile assessed in serum was far less effective in discriminating the groups. Thus, our approach lays the foundation for the development of immunologic "signatures" that could be useful in predicting disease course and monitoring the outcomes of therapy among patients with immune-mediated diseases.

Original languageEnglish (US)
Pages (from-to)7297-7304
Number of pages8
JournalJournal of Immunology
Volume184
Issue number12
DOIs
StatePublished - Jun 15 2010

Fingerprint

Immune System Diseases
Blood Cells
Rheumatoid Arthritis
Biomarkers
Cytokines
Chaperonin 60
Interleukin-17
Interleukin-12
Granulocyte-Macrophage Colony-Stimulating Factor
Human Herpesvirus 4
Immunoassay
Interleukin-4
Interleukin-10
Interleukin-6
Patient Care
Control Groups
Serum
Therapeutics

ASJC Scopus subject areas

  • Immunology
  • Medicine(all)

Cite this

Analysis of complex biomarkers for human immune-mediated disorders based on cytokine responsiveness of peripheral blood cells. / Davis, John Manley III; Knutson, Keith L; Strausbauch, Michael A.; Crowson, Cynthia; Therneau, Terry M; Wettstein, Peter J.; Matteson, Eric Lawrence; Gabriel, Sherine E.

In: Journal of Immunology, Vol. 184, No. 12, 15.06.2010, p. 7297-7304.

Research output: Contribution to journalArticle

@article{f5674528bdd6463d9605e397e14536ea,
title = "Analysis of complex biomarkers for human immune-mediated disorders based on cytokine responsiveness of peripheral blood cells",
abstract = "The advent of improved biomarkers promises to enhance the clinical care for patients with rheumatoid arthritis (RA) and other immune-mediated disorders. We have developed an innovative approach to broadly assess the cytokine responsiveness of human PBMCs using a multistimulant panel and multiplexed immunoassays. The objective of this study was to demonstrate this concept by determining whether cytokine profiles could discriminate RApatients according to disease stage (early versus late) or severity. A 10-cytokine profile, consisting of IL-12, CCL4, TNF-α, IL-4, and IL-10 release in response to stimulation with anti-CD3/anti-CD28, CXCL8 and IL-6 in response to CMVand EBV lysate, and IL-17A, GM-CSF, and CCL2 in response to human heat shock protein 60, easily discriminated the early RA group from controls. These data were used to create an immune response score, which performed well in distinguishing the early RA patients from controls and also correlated with several markers of disease severity among the patients with late RA. In contrast, the same 10-cytokine profile assessed in serum was far less effective in discriminating the groups. Thus, our approach lays the foundation for the development of immunologic {"}signatures{"} that could be useful in predicting disease course and monitoring the outcomes of therapy among patients with immune-mediated diseases.",
author = "Davis, {John Manley III} and Knutson, {Keith L} and Strausbauch, {Michael A.} and Cynthia Crowson and Therneau, {Terry M} and Wettstein, {Peter J.} and Matteson, {Eric Lawrence} and Gabriel, {Sherine E.}",
year = "2010",
month = "6",
day = "15",
doi = "10.4049/jimmunol.0904180",
language = "English (US)",
volume = "184",
pages = "7297--7304",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "12",

}

TY - JOUR

T1 - Analysis of complex biomarkers for human immune-mediated disorders based on cytokine responsiveness of peripheral blood cells

AU - Davis, John Manley III

AU - Knutson, Keith L

AU - Strausbauch, Michael A.

AU - Crowson, Cynthia

AU - Therneau, Terry M

AU - Wettstein, Peter J.

AU - Matteson, Eric Lawrence

AU - Gabriel, Sherine E.

PY - 2010/6/15

Y1 - 2010/6/15

N2 - The advent of improved biomarkers promises to enhance the clinical care for patients with rheumatoid arthritis (RA) and other immune-mediated disorders. We have developed an innovative approach to broadly assess the cytokine responsiveness of human PBMCs using a multistimulant panel and multiplexed immunoassays. The objective of this study was to demonstrate this concept by determining whether cytokine profiles could discriminate RApatients according to disease stage (early versus late) or severity. A 10-cytokine profile, consisting of IL-12, CCL4, TNF-α, IL-4, and IL-10 release in response to stimulation with anti-CD3/anti-CD28, CXCL8 and IL-6 in response to CMVand EBV lysate, and IL-17A, GM-CSF, and CCL2 in response to human heat shock protein 60, easily discriminated the early RA group from controls. These data were used to create an immune response score, which performed well in distinguishing the early RA patients from controls and also correlated with several markers of disease severity among the patients with late RA. In contrast, the same 10-cytokine profile assessed in serum was far less effective in discriminating the groups. Thus, our approach lays the foundation for the development of immunologic "signatures" that could be useful in predicting disease course and monitoring the outcomes of therapy among patients with immune-mediated diseases.

AB - The advent of improved biomarkers promises to enhance the clinical care for patients with rheumatoid arthritis (RA) and other immune-mediated disorders. We have developed an innovative approach to broadly assess the cytokine responsiveness of human PBMCs using a multistimulant panel and multiplexed immunoassays. The objective of this study was to demonstrate this concept by determining whether cytokine profiles could discriminate RApatients according to disease stage (early versus late) or severity. A 10-cytokine profile, consisting of IL-12, CCL4, TNF-α, IL-4, and IL-10 release in response to stimulation with anti-CD3/anti-CD28, CXCL8 and IL-6 in response to CMVand EBV lysate, and IL-17A, GM-CSF, and CCL2 in response to human heat shock protein 60, easily discriminated the early RA group from controls. These data were used to create an immune response score, which performed well in distinguishing the early RA patients from controls and also correlated with several markers of disease severity among the patients with late RA. In contrast, the same 10-cytokine profile assessed in serum was far less effective in discriminating the groups. Thus, our approach lays the foundation for the development of immunologic "signatures" that could be useful in predicting disease course and monitoring the outcomes of therapy among patients with immune-mediated diseases.

UR - http://www.scopus.com/inward/record.url?scp=77953624350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953624350&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.0904180

DO - 10.4049/jimmunol.0904180

M3 - Article

C2 - 20495063

AN - SCOPUS:77953624350

VL - 184

SP - 7297

EP - 7304

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 12

ER -